Rejected from Hepatology? The 7 Best Journals to Submit Next

AASLD guideline relevance. The papers that get the most editorial attention at Hepatology are those that could influence the next AASLD practice guidance update. Research addressing current guideline gaps, testing new treatments for conditions with unmet need, or challenging established recommendations has a built-in advantage.

NAFLD/NASH prominence. Hepatology publishes extensively on metabolic liver disease, and NAFLD/NASH research dominates the journal's content. However, this also means competition in this space is extreme. A well-designed NAFLD cohort study competes against dozens of similar submissions each month.

Balance of clinical and basic. Unlike many clinical journals, Hepatology genuinely values basic liver science. The journal publishes molecular hepatology, liver regeneration biology, hepatic fibrosis mechanisms, and animal model studies alongside clinical trials and epidemiology. But this balance means each category gets limited space.

North American perspective. While Hepatology publishes excellent international research, the editorial team and reviewer pool lean North American. Studies from US and Canadian institutions, or those using North American cohort data, have a slight contextual advantage.

• "NAFLD cohort without novel clinical insights." NAFLD research is so heavily represented at Hepatology that the bar for novelty in this area is extremely high. A large NAFLD cohort study showing expected risk factors and outcomes won't clear the bar unless the methodology is exceptional or the clinical insight is genuinely new.

• "The findings would benefit from validation in an independent cohort." You analyzed one dataset and found something interesting. Hepatology increasingly expects discovery-plus-validation designs, where findings are identified in one cohort and confirmed in a second. Single-cohort studies face skepticism, especially for biomarker and risk prediction papers.

• "Primarily of interest to a subspecialty audience." Hepatology covers all liver disease, but papers that focus narrowly on rare liver conditions, pediatric hepatology, or liver transplant technical details may be redirected to more specialized venues.

• "Mechanistic depth is insufficient for the basic science track." If you submitted to the basic science section, Hepatology expects complete mechanistic stories with in vivo validation, genetic models, and functional assays. Descriptive molecular characterization without functional follow-up rarely makes it.

• "The clinical study design has limitations." Retrospective single-center analyses, studies without adequate propensity matching, and trials with crossover contamination are common rejection triggers. Hepatology's biostatistical reviewers catch these issues consistently.

Before choosing your next journal, a Hepatology manuscript fit check can tell you whether the issue was scope or something more fundamental to address first.

1. Journal of Hepatology

Journal of Hepatology is the EASL flagship and Hepatology's most direct competitor. With an IF around 33.0, it's actually higher-impact than Hepatology, though the two journals occupy the same tier in terms of prestige within the hepatology community. The key difference is editorial geography: JoH has a European editorial board and is particularly receptive to European cohort data, EASL-guideline-relevant research, and studies that address liver disease patterns in European populations.

If Hepatology rejected your paper and the science is strong, JoH should be your first alternative in most cases. The two journals share many reviewers, so if Hepatology's reviewers raised specific concerns, address those before submitting to JoH. But the different editorial perspective means JoH may prioritize different aspects of your work.

Best for: European liver research, EASL guideline-relevant data, NAFLD/NASH, viral hepatitis, all liver disease.

2. Gastroenterology

For papers that span the GI-liver interface, Gastroenterology (AGA journal) is an excellent alternative. The journal publishes hepatology research regularly, especially when the work connects to broader GI themes. Studies on gut-liver axis, portal hypertension with GI complications, or hepatic conditions that affect GI function are natural fits.

Gastroenterology's clinical focus means your paper needs a clear clinical message that resonates with practicing gastroenterologists and hepatologists. If Hepatology rejected your paper for being "too clinical" or "lacking mechanistic depth," Gastroenterology may value that clinical orientation positively.

Best for: Gut-liver axis research, portal hypertension, liver disease with GI overlap, clinical hepatology with GI relevance.

3. Gut

Gut (BMJ) publishes across gastroenterology and hepatology, with a distinctly European editorial perspective and a preference for translational research with mechanistic depth. If Hepatology rejected your paper because the basic science was incomplete, and you have strong translational data that connects molecular findings to clinical liver disease, Gut's editors may find that combination attractive.

Gut expects papers to explain the "why" behind clinical observations. Purely clinical liver studies without a mechanistic angle will face the same challenge at Gut that they might at Hepatology's basic science track.

Best for: Translational hepatology, liver-microbiome interactions, mechanistic liver research with clinical links.

4. Hepatology Communications

Hepatology Communications is the AASLD's companion journal, launched to provide a venue for liver research that doesn't quite clear Hepatology's selectivity bar. The journal has an IF around 5 and is fully open access. If Hepatology's editors offered a transfer, accepting it preserves your reviewer reports and saves significant time.

Don't dismiss Hepatology Communications because of the IF gap. The journal publishes solid hepatology research across all subspecialties, and as an AASLD journal, papers published here are presented at The Liver Meeting and reach the hepatology community effectively.

Best for: Liver research that was competitive at Hepatology but didn't make the cut, all liver disease subspecialties.

5. Liver International

Liver International occupies a solid mid-tier position in hepatology publishing and covers all aspects of liver disease. The journal is particularly strong in epidemiological hepatology, clinical outcomes research, and liver disease in populations that are underrepresented in the North American and European literature.

If your paper was rejected from Hepatology because the study was too small, too regional, or too retrospective for their standards, Liver International may be more receptive. The journal values well-conducted research without demanding that every paper be practice-changing.

Best for: Hepatology epidemiology, clinical liver research, international cohort data, mid-tier liver disease studies.

6. Journal of Viral Hepatitis

For viral hepatitis research specifically, this dedicated journal provides a focused readership. While Hepatology and JoH both publish viral hepatitis papers, those papers compete against NAFLD, HCC, autoimmune liver disease, and every other liver topic. In Journal of Viral Hepatitis, your HBV or HCV paper is evaluated by viral hepatitis specialists without cross-subspecialty competition.

The journal covers all aspects of viral hepatitis: treatment outcomes, resistance, epidemiology, prevention, and basic virology. If your paper is squarely about hepatitis B or C, this focused venue makes sense.

Best for: HBV, HCV, HDV, hepatitis treatment outcomes, viral hepatitis epidemiology, antiviral resistance.

7. JHEP Reports

JHEP Reports is the EASL's open-access companion to Journal of Hepatology, launched in 2019. The journal has quickly established itself with an IF around 8, and it publishes across all hepatology subspecialties. Uniquely, JHEP Reports doesn't charge APCs (funded by EASL), making it one of the few high-quality open-access liver journals with no publication costs.

For papers that JoH would publish if it had more space, JHEP Reports is the natural cascade. If your paper has a European focus and you want open-access visibility without paying an APC, this journal deserves serious consideration.

Best for: European liver research, open-access hepatology, translational liver studies, EASL-relevant clinical data.

NAFLD/NASH paper rejected? Journal of Hepatology first (different editorial perspective, higher IF). If both top-tier journals pass, JHEP Reports and Hepatology Communications are strong mid-tier options within the society journal ecosystems.

Viral hepatitis paper rejected? Journal of Viral Hepatitis for focused viral hepatitis research. Liver International for broader clinical viral hepatitis studies.

Basic liver science rejected? Gut if the work has translational connections. Gastroenterology if there's a clinical angle. For pure basic science, consider Journal of Biological Chemistry or Molecular and Cellular Biology for the mechanistic component.

HCC paper rejected? Consider Clinical Cancer Research or Cancer Research for HCC papers where the cancer biology is the primary contribution. The oncology journals evaluate HCC research differently than liver journals.

Clinical trial rejected? Gastroenterology for GI-liver overlap. Lancet Gastroenterology and Hepatology for practice-changing evidence. AJG for clinical hepatology with a practice focus.

Add a validation cohort. If Hepatology's concern was about single-cohort design, reach out to collaborators for an independent validation dataset. This is increasingly expected for biomarker studies, risk prediction models, and genomics-based findings. Even a smaller validation cohort substantially strengthens the paper.

Address the NAFLD saturation problem. If you're publishing NAFLD/NASH research, your paper needs to offer something the field hasn't seen. New biomarkers, novel therapeutic targets, unique patient populations, or innovative study designs. "Another NAFLD cohort showing expected associations" won't clear the bar at any top-tier liver journal.

Separate clinical and basic components. If your paper contains both clinical outcomes and basic science experiments, consider whether splitting into two focused papers would be more effective. A clinical paper for a clinical hepatology journal and a mechanistic paper for a basic science or translational venue may each be stronger individually.

Tighten the statistical methods. Hepatology's statistical reviewers are thorough, and the same reviewers often review for JoH, Gastroenterology, and Gut. Fix every statistical concern before resubmitting, because the same reviewer may see the paper again at the next journal.

Hepatology is a relatively small field, and the pool of qualified reviewers overlaps significantly across the top journals. That means sloppy resubmissions get noticed. Before your next submission, run your revised manuscript through a manuscript scope and readiness check to check scope alignment, structural completeness, and formatting. Getting the presentation right matters, especially when the same reviewer might see your paper for the second time at a different journal.

Resubmit to the same tier if:

• Reviewers praised the science but identified fixable issues
• The rejection letter mentioned "consider resubmission after revision"
• You can address every concern within 2-3 months
• No competing paper has appeared since your submission

Move to a different journal if:

• The rejection cited scope mismatch, not quality
• Multiple reviewers questioned novelty or significance
• Your timeline needs a decision within 2-3 months
• A specialist journal's readership would value the work more

Reframe before resubmitting anywhere if:

• Reviewers found fundamental methodology concerns
• The narrative needs restructuring, not just editing
• New experiments or analyses are needed
• The rejection exposed a gap between claims and evidence

In our pre-submission review work with manuscripts targeting Hepatology, four patterns generate the most consistent desk rejections worth knowing before resubmission.

Clinical hepatology findings without mechanistic grounding. Hepatology is the flagship journal of the AASLD and publishes work that integrates clinical and mechanistic evidence. We see this failure as the most common pattern in Hepatology desk rejections we review: clinical cohort studies, registry analyses, or treatment outcome papers that do not include any mechanistic investigation of why the observed hepatic finding occurs. In our review of Hepatology submissions, we find that editors consistently require the clinical finding to be accompanied by biological insight into the underlying hepatic mechanism, not deferred to future work.

Basic hepatology research without human tissue validation or disease context. Hepatology expects that basic science findings connect to human liver disease. Papers demonstrating a metabolic pathway, fibrogenic mechanism, or viral replication process in cell lines or animal models without validation in human liver tissue, primary hepatocytes, or a cohort with the relevant liver disease face consistent scope concerns. We see this pattern in Hepatology submissions we review with mechanistically rigorous preclinical data but no human relevance established.

NAFLD or MAFLD studies that do not meet current histological grading standards. Hepatology applies rigorous histological standards to metabolic liver disease studies. We see this failure regularly in manuscripts we review: NAFLD studies using non-standardized histological grading, missing NASH Activity Score or SAF scoring, or biopsy data from cohorts where biopsy timing relative to metabolic intervention is not clearly defined. Editors return these for methodological compliance before peer review.

Hepatitis viral studies without current clinical relevance framing. In the era of highly effective HCV cure and HBV suppression, papers on hepatitis viral mechanisms must connect to questions of clinical relevance: why do some patients fail to respond, what drives HCC risk after viral cure, or what maintains viral reservoirs. We see this pattern in Hepatology submissions we review present virological or immunological findings in the hepatitis context without connecting to the current unresolved clinical problems.

SciRev community data for Hepatology confirms desk rejections typically arrive within days, with post-review first decisions within 6-8 weeks, consistent with the AASLD editorial cadence.